Efficacy and Safety of Ticagrelor and Aspirin in Patients With Moderate Ischemic Stroke: An Exploratory Analysis of the THALES Randomized Clinical Trial

Yongjun Wang, Yuesong Pan, Hao Li, Pierre Amarenco, Hans Denison, Scott R Evans, Anders Himmelmann, Stefan James, Filip Birve, Per Ladenvall, Carlos A Molina, S Claiborne Johnston, THALES Steering Committee and Investigators

Abstract

Importance: Prior trials of dual antiplatelet therapy excluded patients with moderate ischemic stroke. These patients were included in the Acute Stroke or Transient Ischaemic Attack Treated With Ticagrelor and ASA for Prevention of Stroke and Death (THALES) trial, but results have not been reported separately, raising concerns about safety and efficacy in this subgroup.

Objective: To evaluate the efficacy and safety of ticagrelor plus aspirin in patients with moderate ischemic stroke (National Institutes of Health Stroke Scale [NIHSS] score of 4 to 5).

Design, setting, and participants: The THALES trial was a randomized trial conducted at 414 hospitals in 28 countries in January 2018 and December 2019. This exploratory analysis compared patients with moderate stroke (baseline NIHSS score of 4 to 5) with patients with less severe stroke (NIHSS score of 0 to 3). A total of 9983 patients with stroke were included in the present analysis, after excluding 2 patients with NIHSS scores greater than 5 and 1031 patients with transient ischemic attack. Data were analyzed from March to April 2021.

Interventions: Ticagrelor (180-mg loading dose on day 1 followed by 90 mg twice daily on days 2 to 30) or placebo within 24 hours after symptom onset. All patients received aspirin, 300 to 325 mg, on day 1 followed by aspirin, 75 to 100 mg, daily on days 2 to 30. Patients were observed for 30 additional days.

Main outcomes and measures: The primary outcome was time to stroke or death within 30 days. The primary safety outcome was time to severe bleeding.

Results: In total, 3312 patients presented with moderate stroke and 6671 presented with less severe stroke. Of those in the moderate stroke group, 1293 (39.0%) were female, and the mean (SD) age was 64.5 (10.8) years; of those in the less severe stroke group, 2518 (37.7%) were female, and the mean (SD) age was 64.8 (11.2) years. The observed primary outcome event rate in patients with moderate stroke was 7.6% (129 of 1671) for those in the ticagrelor group and 9.1% (150 of 1641) for those in the placebo group (hazard ratio, 0.84; 95% CI, 0.66-1.06); the primary outcome event rate in patients with less severe stroke was 4.7% (158 of 3359) for those in the ticagrelor group and 5.7% (190 of 3312) for those in the placebo group (hazard ratio, 0.82; 95% CI, 0.66-1.01) (P for interaction = .88). Severe bleeding occurred in 8 patients (0.5%) in the ticagrelor group and in 4 patients (0.2%) in the placebo group in those with moderate stroke compared with 16 patients (0.5%) and 3 patients (0.1%), respectively, with less severe stroke (P for interaction = .26).

Conclusions and relevance: In this study, patients with a moderate ischemic stroke had consistent benefit from ticagrelor plus aspirin vs aspirin alone compared with patients with less severe ischemic stroke, with no further increase in the risk of intracranial bleeding or other severe bleeding events.

Trial registration: ClinicalTrials.gov Identifier: NCT03354429.

Conflict of interest statement

Conflict of Interest Disclosures: Dr Wang has received grants from AstraZeneca, Sanofi, and Amgen as well as consulting fees from Sanofi. Dr Amarenco has received grants and personal fees from AstraZeneca, Bristol Myers Squibb, Pfizer, and Boston Scientific; grants from AstraZeneca and Merck; and personal fees from Sanofi, Janssen, GlaxoSmithKline, FibroGen, Shinpoong, Amgen, Bayer, Kowa, Viatris, Novo Nordisk, and Portola Pharmaceuticals. Dr Evans has received personal fees from AstraZeneca and Johnson & Johnson. Dr James has received grants paid to his institution from AstraZeneca, Novartis, Jansen, and Bayer. Dr Johnston has received grants from AstraZeneca and Sanofi. No other disclosures were reported.

Figures

Figure 1.. Flow Diagram
Figure 1.. Flow Diagram
NIHSS indicates National Institutes of Health Stroke Scale; TIA, transient ischemic attack.
Figure 2.. Kaplan-Meier Event Curves for the…
Figure 2.. Kaplan-Meier Event Curves for the Primary Efficacy End Point (Stroke or Death) by Treatment Assignment and Baseline National Institutes of Health Stroke Scale (NIHSS) Group
Figure 3.. Modified Rankin Scale (mRS) Score…
Figure 3.. Modified Rankin Scale (mRS) Score Distribution at Day 30 in Patients With an Ischemic Stroke by Baseline National Institutes of Health Stroke Scale (NIHSS) Group

References

    1. Powers WJ, Rabinstein AA, Ackerson T, et al. . Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2019;50(12):e344-e418. doi:10.1161/STR.0000000000000211
    1. Wang Y, Liu M, Pu C. 2014 Chinese guidelines for secondary prevention of ischemic stroke and transient ischemic attack. Int J Stroke. 2017;12(3):302-320. doi:10.1177/1747493017694391
    1. Liu L, Chen W, Zhou H, et al. ; Chinese Stroke Association Stroke Council Guideline Writing Committee . Chinese Stroke Association guidelines for clinical management of cerebrovascular disorders: executive summary and 2019 update of clinical management of ischaemic cerebrovascular diseases. Stroke Vasc Neurol. 2020;5(2):159-176. doi:10.1136/svn-2020-000378
    1. Dawson J, Merwick Á, Webb A, Dennis M, Ferrari J, Fonseca AC; European Stroke Organisation . European Stroke Organisation expedited recommendation for the use of short-term dual antiplatelet therapy early after minor stroke and high-risk TIA. Eur Stroke J. Published online March 11, 2021. doi:10.1177/23969873211000877
    1. Wang Y, Wang Y, Zhao X, et al. ; CHANCE Investigators . Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med. 2013;369(1):11-19. doi:10.1056/NEJMoa1215340
    1. Johnston SC, Easton JD, Farrant M, et al. ; Clinical Research Collaboration, Neurological Emergencies Treatment Trials Network, and the POINT Investigators . Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA. N Engl J Med. 2018;379(3):215-225. doi:10.1056/NEJMoa1800410
    1. Johnston SC, Amarenco P, Denison H, et al. ; THALES Investigators . Ticagrelor and aspirin or aspirin alone in acute ischemic stroke or TIA. N Engl J Med. 2020;383(3):207-217. doi:10.1056/NEJMoa1916870
    1. Johnston SC, Amarenco P, Denison H, et al. ; THALES Investigators . The Acute Stroke or Transient Ischemic Attack Treated with Ticagrelor and Aspirin for Prevention of Stroke and Death (THALES) trial: rationale and design. Int J Stroke. 2019;14(7):745-751. doi:10.1177/1747493019830307
    1. GUSTO Investigators . An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 1993;329(10):673-682. doi:10.1056/NEJM199309023291001
    1. Fischer U, Baumgartner A, Arnold M, et al. . What is a minor stroke? Stroke. 2010;41(4):661-666. doi:10.1161/STROKEAHA.109.572883
    1. Xiong Y, Gu H, Zhao XQ, et al. . Clinical characteristics and in-hospital outcomes of varying definitions of minor stroke: from a large-scale nation-wide longitudinal registry. Stroke. 2021;52(4):1253-1258. doi:10.1161/STROKEAHA.120.031329
    1. Pan Y, Elm JJ, Li H, et al. . Outcomes associated with clopidogrel-aspirin use in minor stroke or transient ischemic attack: a pooled analysis of Clopidogrel in High-Risk Patients With Acute Non-Disabling Cerebrovascular Events (CHANCE) and Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) trials. JAMA Neurol. 2019;76(12):1466-1473. doi:10.1001/jamaneurol.2019.2531
    1. Ferreiro JL, Sibbing D, Angiolillo DJ. Platelet function testing and risk of bleeding complications. Thromb Haemost. 2010;103(6):1128-1135. doi:10.1160/TH09-11-0799
    1. Tillman H, Johnston SC, Farrant M, et al. . Risk for major hemorrhages in patients receiving clopidogrel and aspirin compared with aspirin alone after transient ischemic attack or minor ischemic stroke: a secondary analysis of the POINT randomized clinical trial. JAMA Neurol. 2019;76(7):774-782. doi:10.1001/jamaneurol.2019.0932
    1. Wang D, Gui L, Dong Y, et al. . Dual antiplatelet therapy may increase the risk of non-intracranial haemorrhage in patients with minor strokes: a subgroup analysis of the CHANCE trial. Stroke Vasc Neurol. 2016;1(2):29-36. doi:10.1136/svn-2016-000008
    1. Park JH, Ovbiagele B. Relationship of functional disability after a recent stroke with recurrent stroke risk. Eur J Neurol. 2016;23(2):361-367. doi:10.1111/ene.12837
    1. Wang YL, Pan YS, Zhao XQ, et al. ; CHANCE investigators . Recurrent stroke was associated with poor quality of life in patients with transient ischemic attack or minor stroke: finding from the CHANCE trial. CNS Neurosci Ther. 2014;20(12):1029-1035. doi:10.1111/cns.12329
    1. Ganesh A, Luengo-Fernandez R, Wharton RM, Rothwell PM; Oxford Vascular Study . Ordinal vs dichotomous analyses of modified Rankin Scale, 5-year outcome, and cost of stroke. Neurology. 2018;91(21):e1951-e1960. doi:10.1212/WNL.0000000000006554
    1. Wu CM, McLaughlin K, Lorenzetti DL, Hill MD, Manns BJ, Ghali WA. Early risk of stroke after transient ischemic attack: a systematic review and meta-analysis. Arch Intern Med. 2007;167(22):2417-2422. doi:10.1001/archinte.167.22.2417
    1. Amarenco P, Lavallée PC, Labreuche J, et al. ; Investigators . One-year risk of stroke after transient ischemic attack or minor stroke. N Engl J Med. 2016;374(16):1533-1542. doi:10.1056/NEJMoa1412981
    1. Amarenco P, Denison H, Evans SR, et al. ; THALES Steering Committee and Investigators . Ticagrelor added to aspirin in acute nonsevere ischemic stroke or transient ischemic attack of atherosclerotic origin. Stroke. 2020;51(12):3504-3513. doi:10.1161/STROKEAHA.120.032239
    1. Cucchiara B, Elm J, Easton JD, et al. . Disability after minor stroke and transient ischemic attack in the POINT trial. Stroke. 2020;51(3):792-799. doi:10.1161/STROKEAHA.119.027465
    1. Cucchiara B, George DK, Kasner SE, et al. . Disability after minor stroke and TIA: a secondary analysis of the SOCRATES trial. Neurology. 2019;93(7):e708-e716. doi:10.1212/WNL.0000000000007936
    1. Amarenco P, Denison H, Evans SR, et al. ; THALES Steering Committee and Investigators . Ticagrelor added to aspirin in acute ischemic stroke or transient ischemic attack in prevention of disabling stroke: a randomized clinical trial. JAMA Neurol. 2020;78(2):1-9. doi:10.1001/jamaneurol.2020.4396
    1. Reeves M, Khoury J, Alwell K, et al. . Distribution of National Institutes of Health Stroke Scale in the Cincinnati/Northern Kentucky Stroke Study. Stroke. 2013;44(11):3211-3213. doi:10.1161/STROKEAHA.113.002881

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅